thymosin beta-4 fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Permeabilization involves treatment of cells with (usually) a mild surfactant. This treatment dissolves cell membranes, and allows larger dye molecules into the cell's interior. Mounting usually involves attaching the samples to a glass microscope slide for observation and analysis. In some cases, cells may be grown directly on a slide. For samples of loose cells (as with a blood smear or a pap smear) the sample can be directly applied to a slide. For larger pieces of tissue, thin sections (slices) are made using a microtome; these slices can then be mounted and inspected.
The expected structure of the neurotoxin consists of four disulfide bonds, which are arranged in the following manner: 1–4, 2–5, 3–8, 6–7. Three of the disulfide bonds are believed to form an inhibitor cystine knot, which is known to increase resistance to heat denaturation and proteolysis. Transcriptomics has revealed the presence of both an N-terminal signal peptide and a pro peptide, which are cleaved after translation.
Stern (1960), traditionalist architect, dean of the Yale School of Architecture Scott Burton (1962), urban sculptor Bernard Cywinski (1962), architect and co-founder of the firm Bohlin Cywinski Jackson, which designed the Liberty Bell center in Philadelphia, the Apple Fifth Avenue store, and the Seattle City Hall Stephen A. Lesser (1966), architect Gordon Gahan (1967)*, photographer for National Geographic Edwin Schlossberg (1967), designer, author, artist; husband of Caroline Kennedy Francis Levy (1969), comic book artist Greg Wyatt (1971), sculptor-in-residence at the Cathedral of St. John the Divine, known for designing the Peace Fountain Timothy Greenfield-Sanders (1974), photographer and documentary filmmaker Michael Middleton Dwyer (1975), architect known for his restoration works James Sanders (1976), architect who co-wrote New York: A Documentary Film with Ric Burns '78 Ephraim Rubenstein (1978), artist Peter Pennoyer (1980), architect known for the renovation of the Colony Club and the Knickerbocker Club, great-great-grandson of J.P. Morgan John Arcudi (1983), cartoonist for DC Comics and creator of The Mask and Major Bummer Jacob Collins (1986), realist painter, founder of the Grand Central Academy of Art Lance Hosey (1987), architect, author of The Shape of Green; chief sustainability officer of the global architectural firm RTKL Associates Matthew Weinstein (1987), visual artist, son of physician I.
=== Illinois === Phlebotomists are not licensed in Illinois but must have a high school diploma and have completed a training program to practice. Certification is not required and phlebotomists do not fall under the Illinois Clinical Laboratory Act. In 2020, Illinois passed a bill requiring the Illinois Department of Public Health to triannually develop training materials for drawing blood from children and adults with intellectual and developmental disabilities and for facilities to ensure the training is incorporated for phlebotomists. There have been bills to introduce phlebotomy licensure in Illinois, but have been unsuccessful.
Sources: en.wikipedia.org
=== Detection in biological fluids === Atomoxetine may be quantitated in plasma, serum, or whole blood to distinguish extensive versus poor metabolizers in those receiving the drug therapeutically, to confirm the diagnosis in potential poisoning victims, or to assist in the forensic investigation in a case of fatal overdosage.
Peukert further commented that the Federal Republic of Germany never paid reparations to those homosexuals who survived the concentration camps as Paragraph 175 was considered a "healthy law" that was worth keeping, and those homosexual survivors who suffered so much in the concentration camps remained outcasts in post-war Germany. Writing in the 1970s and 1980s at a time when Paragraph 175 was still in effect, Peukert argued that the sort of homophobia which made the Nazi persecution of homosexuals possible, was still very much present in modern West Germany. In the same way, Peukert wrote the "everyday racism" that allowed ordinary people to accept violence directed against "others" in the Third Reich had not disappeared, noting that many ordinary Germans were willing to accept neo-Nazi skinheads beating up Turkish guest workers because they were "foreigners". Crew writing in 1992 wrote that the "recent epidemic of violence against 'foreigners' in both the 'old' and 'new' Länder suggests he may have been right". Peukert wrote that though the Nazis did use an "anti-modernist" disclosure inspired by the theories of Houston Stewart Chamberlain, their solution to the problems of "classical modernity" were not "merely backward-looking". Peukert wrote the attempt to create the volksgemeinschaft was not an effort to return to the pre—industrial age, but rather a purged and cleansed "classical modernity".
Buddhism is the most widely practised religion, with 30.9% of residents declaring themselves adherents in the 2020 census. Christianity was the second largest religion at 17.1%, followed by Islam (15.0%), Taoism and folk beliefs (7.3%) and Hinduism (5.4%). Over one-fifth of the population had no religious affiliation. The proportion of Christians, Muslims, and the nonreligious slightly increased between 2010 and 2020, while the proportion of Buddhists and Taoists slightly decreased; Hinduism and other faiths remained largely stable in their share of the population. Singapore hosts monasteries and Dharma centres from all three major traditions of Buddhism: Theravada, Mahayana, and Vajrayana. Most Buddhists in Singapore are Chinese and adhere to the Mahayana tradition, owing to decades of missionary activity from China. However, Thailand's Theravada Buddhism has seen growing popularity among the populace (not only the Chinese) during the past decade. Soka Gakkai International, a Japanese Buddhist organisation, is practised by many people in Singapore, and mostly by those of Chinese descent. Tibetan Buddhism has also made slow inroads into the country in recent years.
Sources: en.wikipedia.org
=== Grand Lodge of South Carolina === On March 27, 1818, the Grand Lodge of South Carolina chartered La Constancia Lodge, No. 50. On March 31, 1820, they chartered La Amenidad Lodge, No. 52. Both of these were chartered in Havana. In 1821, the Grand Lodge of Ancient Freemasons sent a communication to the Grand Lodge of South Carolina that a new Grand Lodge had been formed in Cuba, and La Amenidad Lodge, No. 52 had expressed its desire to transfer to the new Grand Lodge. The Grand Lodge of South Carolina accepted the arrangement. However, La Constancia Lodge, No. 50, remained a part of the Grand Lodge of South Carolina until its members surrendered its warrant around the year 1824, stating that their decision was made "in consequence of the religious and political persecutions to which they were subjected."
Subsequently, in 1989, New York became the first state to address this issue by implementing regulations through the Health Code, marking a pivotal moment in the regulation of resident hours. These regulations, integrated into the state hospital code, included duty hour limits and supervision enhancements advocated by the Bell Commission. However, despite the issuance of regulations, compliance was slow to materialize, and a decade later, site visits revealed widespread noncompliance with the established limits. The efforts to address and regulate resident work hours culminated nationally in 2003 when the ACGME (Accreditation Council for Graduate Medical Education) mandated these limits across the United States.
==== Shortness of breath ==== Opioids may help with shortness of breath particularly in advanced diseases such as cancer and COPD. However, findings from two recent systematic reviews of the literature found that opioids were not necessarily more effective in treating shortness of breath in patients who have advanced cancer.
== Animal toxicity == κ-Bungarotoxin can selectively bind to neuronal nAChRs, by which it inhibits or blocks neurotransmission. The toxin shows different effects in diverse animals. For instance, in insects, κ-bungarotoxin blocks transmission at the cholinergic synapse between mechanosensory neurons and an interneuron in the terminal abdominal ganglion. It also blocks nAChRs on a motor neuron in the metathoracic ganglion of a cockroach. Muscle nAChRs in nematodes show a higher sensitivity to κ-bungarotoxin than the alpha-version of the bungarotoxin. Compared to another toxin, only a concentration of 10 nM was needed to block the muscle receptor instead of 100 nM. This also means that there is a difference in effects of the toxin on different animals, because it appears that nematodes are more sensitive to κ-bungarotoxin than insects. In chicks, the κ-bungarotoxin seems to bind with a low affinity to skeletal muscle nicotinic receptors[12]. Although the effects on the chicks have not been described, following the mechanism it is expected that there will be either none or a small amount of muscle paralysis at a low concentration of κ-bungarotoxin. However, the toxin does bind with high affinity to the neuronal nicotinic receptors in the autonomic ganglia, which can block the synaptic transmission already at a low concentration. This would cause effects like respiratory failure.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.